

## CLOSE OF CLEANSING PROSPECTUS

Wellnex Life Limited (**ASX: WNX**) advises that it has closed the Offer pursuant to its Cleansing Prospectus dated 7 March 2024 (as extended to 7 February 2025 via ASX announcement dated 31 January 2025), so as to facilitate the secondary trading of those shares to be issued.

No shares were issued under the Offer as contemplated in the Cleansing Prospectus.

**-ENDS-**

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX).

### For further information, please contact:

**Wellnex Life Limited (ASX:WNX)**

**George Karafotias**

Chief Executive Officer

P: +61 3 8399 9419

E: [george.k@wellnexlife.com.au](mailto:george.k@wellnexlife.com.au)

### About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial

growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: [www.wellnexlife.com.au/](http://www.wellnexlife.com.au/)